Cancer Science Laboratory, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, 603203, Chengalpattu, India.
Curr Aging Sci. 2024;17(1):16-30. doi: 10.2174/0118746098241507231127114248.
Various developments have been observed in the treatment of cancer patients, such as higher survival rates and better treatment outcomes. However, expecting similar outcomes in older patients remains a challenge. The main reason for this conclusion is the exclusion of older people from clinical trials for cancer drugs, as well as other factors, such as comorbidity, side effects, age-related frailties and their willingness to undergo multiple treatments. However, the discovery of new techniques and drug combinations has led to a significant improvement in the survival of the elderly population after the onset of the disease. On the other hand, cancer treatments have not become more complex for the younger population when compared to the older population, as the younger population tends to respond well to treatment trials and their physiological conditions are stable in response to treatments. In summary, this review correlates recent cancer treatment strategies and the corresponding responses and survival outcomes of older and younger patients.
在癌症患者的治疗中观察到了各种进展,例如更高的生存率和更好的治疗结果。然而,期望老年患者获得类似的结果仍然是一个挑战。得出这一结论的主要原因是将老年人排除在癌症药物的临床试验之外,以及其他因素,如合并症、副作用、与年龄相关的脆弱性以及他们接受多次治疗的意愿。然而,新技术和药物组合的发现导致疾病发作后老年人群的生存率显著提高。另一方面,与老年人群相比,年轻人群的癌症治疗并没有变得更加复杂,因为年轻人群往往对治疗试验反应良好,并且他们的生理状况对治疗反应稳定。总之,本综述将癌症治疗策略的最新进展与老年和年轻患者的相应反应和生存结果相关联。
Dan Med J. 2012-4
Cancer Control. 2015-4
J Am Coll Surg. 2001-6
Urol Oncol. 2009
Internist (Berl). 2010-3
Cancer Rep (Hoboken). 2023-2
Nanoscale Adv. 2021-4-14
Lancet Healthy Longev. 2021-10
Antioxidants (Basel). 2022-7-28
Cancer Cell Int. 2022-8-15
Trends Cancer. 2022-11
CA Cancer J Clin. 2022-9